Back to Resources
Key Research Findings
40%
Reduction in Review Effort
Implementation of Review by Exception (RBE) eliminates manual cross-checking of non-deviating process steps.
50%
Decrease in Documentation Errors
Algorithmic data entry validation at the point of execution prevents missing signatures, illegible entries, and calculation mistakes.
75%
Faster Record Retrieval
Instantaneous system access replaces legacy warehouse physical logistics during health authority inspections.
14 Days
Average Cycle Time Saved
Compressed timelines from batch execution completion to final Qualified Person (QP) market release authorization.
Guide Overview & Chapters
Written specifically for operational, quality, and technology executives, this document outlines operational strategies, validation blueprints, cost models, and architectures to transition pharma sites from manual records to digital execution.
Table of Contents (30 Pages)
01Executive Summary
02The State of Pharmaceutical Manufacturing in 2026
03Why Paper Batch Records are Becoming Unsustainable
04The True Cost of Paper Batch Records
05Pharma Manufacturing Maturity Model
06What is eBMR?
07How eBMR Works
08Traditional Batch Records vs eBMR
09Business Benefits of eBMR
10Reducing Human Errors
11Improving Data Integrity
12Accelerating Batch Release
13Review by Exception (RBE)
14Regulatory Expectations
1521 CFR Part 11 Requirements
16Data Integrity Requirements (ALCOA+)
17GMP and Annex 11 Considerations
18eBMR Implementation Challenges
19Why eBMR Projects Fail
20The 7 Pillars of Successful eBMR Deployment
21eBMR Readiness Assessment
22ROI Calculation Framework
235-Year Cost Analysis
24Vendor Evaluation Framework
25Connected Manufacturing Architecture
26Future of Digital Manufacturing
27QA Stack eBMR Platform Overview
28Implementation Roadmap
29Executive Checklist